Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02952989 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Seagen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT02952989 is a Phase 1 study that was terminated before completion, run by Seagen. The registered enrollment target is 47 participants.
The verdict
NCT02952989, a Phase 1 study, was terminated before completion, sponsored by Seagen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
This study is being done to find out the side effects (unwanted effects) that are caused in patients with cancers who are given SGN-2FF. This study will also attempt to find the most suitable dose in the disease or condition being studied and look at other effects of SGN2FF, including its effect on cancer. This study has several different parts. Part A will try to find the highest safe dose. Part B will enroll more patients to be treated at the highest safe dose or a lower dose to better understand how well SGN-2FF is tolerated. Part C will try to find the highest safe dose of SGN-2FF when it is given combined with pembrolizumab. Pembrolizumab is a standard treatment for cancer. Part D will enroll more patients to be treated at the highest safe dose of SGN-2FF combined with pembrolizumab or a lower dose of SGN-2FF to better understand how well SGN-2FF is tolerated when it is given with pembrolizumab.
Interventions
- DRUG pembrolizumab
- DRUG SGN-2FF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2017-02-23 |
| Est. Completion | 2019-06-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02952989
The ClinicalTrials.gov registry entry for NCT02952989 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pembrolizumab is the first listed.
NCT02952989 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02952989 about?
NCT02952989 is a clinical study titled "A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors". This study is being done to find out the side effects (unwanted effects) that are caused in patients with cancers who are given SGN-2FF. This study will also attempt to find the most suitable dose in the disease or condition being studied and look at other effects of SGN2FF, including its effect on ...
What is the current status of trial NCT02952989?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2017-02-23. Estimated completion is 2019-06-24.
What interventions are being tested in trial NCT02952989?
The interventions under investigation include: pembrolizumab (DRUG), SGN-2FF (DRUG).
Who is sponsoring clinical trial NCT02952989?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.